Contributions
Stay tuned—this is where the team’s scientific contributions will be shared.
Accolades
Check back soon to see how this team is being recognized.
In the News
Slowing the ‘Parkinson’s pandemic’
07/24/2026 — To investigate possible links between Parkinson’s and air pollutants and certain pesticides, Dr. Bronstein is leading a three-year project being conducted with researchers at Cedars-Sinai and the University of Münster in Germany. The effort was recently awarded $9 million by Aligning Science Across Parkinson’s and The Michael J. Fox Foundation for Parkinson’s Research. .
Decoding the Blueprint: Advancing Personalized Parkinson’s Treatments
05/21/2026 — In our community, we often hear: “If you’ve met one person with Parkinson’s, you’ve met one person with Parkinson’s.” This isn’t just an adage — it’s a biological reality. This radical variability is exactly what makes the disease so difficult to outsmart. We’ve learned that a puzzle this fragmented cannot be solved with a single, broad stroke. Our goal isn’t to find one answer for everyone, but the right answer for the right person at the right time.
UCLA to lead $9M study on pesticides’, air pollutants’ link to Parkinson’s disease risk
05/14/2026 — UCLA Health will lead a $9 million, multi-institution research project to further elucidate the link between exposure to pollutants including certain pesticides, air pollution and the increased risk of Parkinson’s disease.
Cedars-Sinai Adds Stem Cell Skill to Key Parkinson’s Disease Study
05/04/2026 — Cedars-Sinai Health Sciences University investigators are bringing their stem cell expertise to a collaboration with two other academic medical centers with the goal of clarifying the connection between pesticide exposure and Parkinson’s disease.
MJFF and ASAP Invest $261M in Global Network for Parkinson’s Research
04/30/2026 — Parkinson’s News Today reports that ASAP and The Michael J. Fox Foundation are investing $261 million to expand the Collaborative Research Network (CRN) to better understand what drives Parkinson’s disease and to accelerate the development of more personalized therapies.
